Followers | 679 |
Posts | 140715 |
Boards Moderated | 37 |
Alias Born | 03/10/2004 |
Sunday, September 06, 2020 10:53:54 AM
By: Zacks Equity Research | September 4, 2020
A month has gone by since the last earnings report for CVS Health (CVS). Shares have lost about 5.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is CVS Health due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
CVS Health Q2 Earnings Top Estimates on Robust Health Care Benefit Sales
CVS Health's second-quarter 2020 adjusted earnings per share (EPS) of $2.64 increased 39.7% year over year and exceeded the Zacks Consensus Estimate by 36.8%. The adjusted EPS figure takes into account certain integration costs pertaining to the buyout of Aetna and asset amortization costs along with other adjustments.
On a reported basis, the company’s earnings of $2.26 per share improved 51.7% year over year.
Total revenues in the second quarter rose 3% year over year to $65.34 billion. The top line also beat the Zacks Consensus Estimate by 1.9%.
Quarter in Detail
Pharmacy Services revenues were up a marginal 0.1% to $34.89 billion in the reported quarter. Growth was sluggish as year-over-year improvements in specialty pharmacy and brand inflation were largely offset by client losses and continued price compression.
Total pharmacy claims processed rose 3.4% on a 30-day equivalent basis, attributable to strong net new business, partially offset by reduced new therapy prescriptions on lower provider visits.
Revenues from CVS Health’s Retail/LTC were up 1% year over year to $21.66 billion. In the quarter, favorable pharmacy drug mix, growth in retail pharmacy prescription volume and brand inflation were partially offset by continued reimbursement pressure, the impact of recent generic introductions, decreased long-term care prescription volume and lower front store revenues.
Front store revenues decreased 4.6% year over year on reduced customer traffic in the retail pharmacies due to shelter-in-place orders. Prescriptions filled too dropped 1.1% on a 30-day equivalent basis on reduced new therapy prescriptions due to lower provider visits through the second quarter and decreased long-term care prescription volume. This was partially offset by the continued adoption of patient care programs.
Within Health Care Benefits segment, the company registered revenues worth $18.47 billion in the second quarter, up 6.1% year over year. The improvement was primarily driven by membership growth in the Health Care Benefits segment's government products and favorable impact of the reinstatement of the HIF (Health Insurer Fee) for 2020. This was partially offset by the absence of the financial results of Aetna's standalone Medicare Part D prescription drug plans (PDPs) and membership declines in Commercial insured products.
Margin
Gross profit improved 17.4% to $13.3 billion. Gross margin expanded 250 basis points (bps) to 20.4% in spite of 0.1% decline in total cost of product sold and benefit costs. Operating margin in the quarter under review grew 191 bps to $7.16 billion on a 40.5% rise in operating profit to $4.68 billion.
Outlook
CVS Health raised its 2020 adjusted EPS and cash flow guidance.
Adjusted EPS is expected in the band of $7.14-$7.27 (from the earlier band of $7.04-$7.17). The Zacks Consensus Estimate for 2020 earnings is pegged at $7.11.
Full-year operating cash flow is expected in the range of $11 billion-$11.5 billion compared with the earlier projection of $10.5 billion-$11.0 billion.
Further, the company projects higher utilization in its Health Care Benefits segment in the second half of 2020 than in the first half and continued significant COVID-19 related investments in the remainder of the year.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month. The consensus estimate has shifted -16.31% due to these changes.
VGM Scores
Currently, CVS Health has a great Growth Score of A, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of A on the value side, putting it in the top 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, CVS Health has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Read Full Story »»»
DiscoverGold
Information posted to this board is not meant to suggest any specific action, but to point out the technical signs that can help our readers make their own specific decisions. Caveat emptor!
• DiscoverGold
Recent CVS News
- Aetna Better Health of Michigan recommended for CHCP contract • PR Newswire (US) • 04/09/2024 04:00:00 PM
- CVS Health® expands pharmacy tuition assistance and scholarship programs • PR Newswire (US) • 04/03/2024 12:00:00 PM
- CVS Health to hold first quarter 2024 earnings conference call • PR Newswire (US) • 04/01/2024 01:00:00 PM
- CVS Health® invests more than $3M in organizations improving health outcomes in Phoenix • PR Newswire (US) • 03/27/2024 06:00:00 PM
- CVS Health announces quarterly dividend • PR Newswire (US) • 03/21/2024 02:55:00 PM
- AM Best Affirms Credit Ratings of Most of CVS Health Corporation’s Aetna Inc. Subsidiaries; Withdraws Credit Ratings of Members of Texas Health Aetna • Business Wire • 03/13/2024 09:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 11:09:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:21:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:20:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:18:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 09:37:48 PM
- CVS Health invests nearly $35 million in affordable housing in Hawai'i • PR Newswire (US) • 02/22/2024 01:45:00 AM
- CVS Health to participate at the 45nd Annual Raymond James Institutional Investors Conference • PR Newswire (US) • 02/21/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 11:46:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/16/2024 09:12:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 10:15:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 10:14:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 10:13:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 10:12:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 10:08:19 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 10:02:40 PM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 02/09/2024 10:14:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/07/2024 11:52:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 11:33:20 AM
- CVS HEALTH REPORTS FOURTH QUARTER AND FULL-YEAR 2023 RESULTS • PR Newswire (US) • 02/07/2024 11:30:00 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM